JeanMarie Guenot is the president and CEO of Amphivena Therapeutics. This is an organization that aims at restoring life to the cancer patients by eradicating the cancer cells while strengthening a patient’s own immune system.

 

According to CrunchBase, JeanMarie Guenot studied Physical and Medical chemistry specializing in protein structure prediction, X-ray and NMR confinement, quantum mechanical and semi-empirical methods for molecular dynamics and drug design. She has a Ph.D. from the University of San Francisco, California and An MBA from Wharton School, University of Pennsylvania.

 

She has over 20 years of working experience in both private and public companies in different roles. She started her career as an entrepreneur in Atlas ventures where she managed capital investments and played a role in building life science companies. Her medical/ scientific career started at Hoffmann-La ROCHE where she was the principal scientist in charge of developing of drugs that cure autoimmune diseases, inflammation, metabolic diseases and oncology. Before moving to Amphivena Therapeutics, she founded the SKS Ocular. This an ophthalmic company that releasing ocular drug delivery techniques as well as ocular inflammation and mass degeneration.

At Amphivena Therapeutics, JeanMarie Guenot leads a host of other equal professionals in the medical field to do research and develop antibody therapy to address blood cancer. Starting its operation in July 2013, the firm has partnered with other institutions that are passionate and interested in the therapy of passionate by bringing on board their expertise, experience, and academic qualifications. Their latest research led to the discovery of Vitro and in vivo killing of AML using tetravalent bispecific CD33/CD3 TandAbs in May 2015.

 

As a woman who has accomplished so much both as an entrepreneur and in the medical fraternity, she is indeed a female role model to the whole world. In 2005, she was awarded Bio Business Network Innovative Bio-Partnering and in 2006, she was awarded for a deal of distinction from the Licensing Executive Society. She is a hard worker and her professional skills have made her succeed both in her work and in life in general. Her most notable achievement, however, will be the 50:50 deal she made between Hoffman-La Roche and PLD to develop and commercialize their drugs.

Publications Authored by JeanMarie Guenot

Brad Reifler states that according to a study published in the journal Environmental Health Perspectives, a chemical additive found in most carbonated beverages and laxatives, which has been deemed as safe by government health authorities, may prompt the onset of obesity in individuals.

The chemical additive, dioctyl sodium sulfosuccinate (DOSS), assists in the blending of ingredients and is a primary additive in the formulation, Corexit, a chemical dispersant that was utilized to break up, and disperse oil accumulations, in the Gulf of Mexico, during the major oil spill catastrophe, in 2010. Though the chemical has been used in various applications for over 60 years, only now has it garnered attention from health advocacy groups, concerned about its impact on individuals.

The non-profit health and environmental organization, the Environmental Working Group, indicated that DOSS is currently an additive in popular consumer products such as Hawaiian Punch Fruit Drinks, Coca-Cola Company product, “Fanta” soda, and Flavor-Air brand soft drink products. The potential that DOSS is an additive in other products is potentially high, as quantities added to formulas can be small enough to not reported to governmental agencies.

The United States Food and Drug Administration approved DOSS as “generally recognized as safe,” when Cytec Industries sought use approval in 1998. No inquiries were made by the government, and in essence, rubber-stamped the application for approval. FDA spokesperson Marianna Naum indicated the study would be assessed, but will decline further comment.